albumin-bound paclitaxel / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 274 Diseases   1060 Trials   1060 Trials   12189 News 


«12...678910111213141516...178179»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment open, Trial initiation date:  Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC (clinicaltrials.gov) -  Apr 2, 2024   
    P2,  N=70, Recruiting, 
    Furthermore, the developed GBM-on-a-chip model provides a potential ex vivo platform for innovative cell-based therapies and tailored therapeutic strategies for GBM. Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Jan 2024
  • ||||||||||  Lipusu (liposomal paclitaxel) / Luye Group
    Journal, Metastases:  Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy. (Pubmed Central) -  Mar 29, 2024   
    The precise molecular switch also helped to increase the PTX maximum tolerated dose from 25 In in vivo study, PTX-Rh2-lipo effectively inhibiting the growth of advanced breast tumors and outperformed most reported PTX formulations, including Lipusu
  • ||||||||||  APG-1387 / Ascentage Pharma
    Trial completion date, Trial primary completion date, Metastases:  APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) -  Mar 29, 2024   
    P1/2,  N=44, Recruiting, 
    In in vivo study, PTX-Rh2-lipo effectively inhibiting the growth of advanced breast tumors and outperformed most reported PTX formulations, including Lipusu Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
  • ||||||||||  albumin-bound paclitaxel / Generic mfg.
    Journal, Metastases:  Regimen Selection by Narrative Approach in Patients with Advanced Gastric Cancer-Paclitaxel or Nab-Paclitaxel? (Pubmed Central) -  Mar 22, 2024   
    Here, we report a case of metachronous oligo-hepatic and peritoneal metastases in a patient who survived without recurrence for 3 Questionnaire survey suggests that we may select the patients for nab-PTX properly by clarifying the inconvenience of daily life associated with premedication, the way of transportation for visiting hospital, and the benefits by shortening of infusion time.
  • ||||||||||  albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
    Enrollment open, Metastases:  PTCA199-9: Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) -  Mar 21, 2024   
    P2,  N=30, Recruiting, 
    Questionnaire survey suggests that we may select the patients for nab-PTX properly by clarifying the inconvenience of daily life associated with premedication, the way of transportation for visiting hospital, and the benefits by shortening of infusion time. Not yet recruiting --> Recruiting
  • ||||||||||  ORIN1001 / Fosun Pharma
    Trial completion date, Trial primary completion date, Metastases:  ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer (clinicaltrials.gov) -  Mar 18, 2024   
    P1/2,  N=150, Active, not recruiting, 
    The randomized controlled trial is necessary to validate our findings. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
  • ||||||||||  Review, Journal, Metastases:  Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma. (Pubmed Central) -  Mar 18, 2024   
    For mPDAC, FOLFIRINOX or gemcitabine plus nab-paclitaxel are the current first-line treatments...Current understanding of the molecular signature and immune landscape of PDAC has motivated the emergence of different targeted and immune-based therapeutic approaches, some of which have shown promising results. The purpose of this review is to discuss the new targets and new drugs for mPDAC in terms of specific pathogenic factors such as metabolic vulnerability, DNA damage repair system, tumor microenvironment and immune system, in order to identify potential vulnerabilities in mPDAC patients and hopefully improve the prognosis of mPDAC patients.
  • ||||||||||  TTX-030 / AbbVie, Trishula Therap
    Enrollment open, Trial initiation date, Metastases:  Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients (clinicaltrials.gov) -  Mar 18, 2024   
    P2,  N=180, Recruiting, 
    Second-line PD-1 inhibitor combined with albumin paclitaxel and apatinib showed certain efficacy and safety in patients with mGC. Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Mar 2024
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Metastases:  Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) -  Mar 15, 2024   
    P2,  N=104, Completed, 
    This study meets the primary endpoint showing potential efficacy of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin, with an acceptable safety profile, in patients with resectable locally advanced HNSCC. Active, not recruiting --> Completed | N=71 --> 104 | Trial completion date: Dec 2024 --> Dec 2023
  • ||||||||||  ivospemin (SBP-101) / Panbela Therap
    Enrollment change, Trial completion date, Trial primary completion date, Metastases:  ASPIRE: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (clinicaltrials.gov) -  Mar 15, 2024   
    P2/3,  N=600, Recruiting, 
    Trial completion date: Dec 2023 --> Dec 2024 N=150 --> 600 | Trial completion date: May 2024 --> Jan 2027 | Trial primary completion date: May 2024 --> Aug 2026
  • ||||||||||  UCT-01-097 / 1200 Pharma
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases:  UCT01097-001: First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Mar 15, 2024   
    P1,  N=32, Terminated, 
    N=106 --> 32 | Trial completion date: Aug 2024 --> Feb 2024 | Recruiting --> Terminated | Trial primary completion date: Sep 2023 --> Feb 2024; Stopped for strategic business reasons. The decision to stop the study was not connected to any safety concerns, or new risk associated with the study product, intervention, or procedures.
  • ||||||||||  cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
    EFFICACY OF FULLY COVERED SELF-EXPANDABLE METAL STENTS IN PATIENTS WITH HILAR CHOLANGIOCARCINOMA UNDERGOING TRIPLET CHEMOTHERAPY REGIMEN (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_7756;    
    Notably, a statistically significant difference ( p <0.05) in cumulative stent patency was observed between plastic stents and FCSEMS in both groups. Conclusions : When bilateral EBD was performed using 6mm FCSEMS in patients with unresectable hilar CCC receiving GCP chemotherapy, better stent patency was shown in both the locally advanced and metastatic groups compared to that of plastic stent, and this was confirmed as a significant result.
  • ||||||||||  DELTA RADIOMIC FEATURES PREDICT RESECTION MARGIN STATUS AND OVERALL SURVIVAL IN NEOADJUVANT-TREATED PANCREATIC CANCER PATIENTS (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_7565;    
    The model that combined preoperative clinical variables (pre-NAT CA19-9, the change in CA19-9 after NAT (?CA19-9), and DRF outperformed all the other models (clinical feature-based models and other radiomics feature-based models) in predicting OS (UTSW: 0.73; Humanitas: 0.66), DFS (UTSW: 0.75; Humanitas: 0.64), and PRMS (UTSW 0.73; Humanitas: 0.69) in both the discovery and validation cohorts. Conclusions Our externally validated model that incorporates delta radiomic features with preoperative clinical data shows promise as a pre-operative tool in predicting OS and DFS and in estimating the risk of an R0 resection in NAT-treated PDAC patients.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    ENDOSCOPIC FULL-THICKNESS RESECTION AFTER CONVERSION THERAPY: ORGAN PRESERVATION STRATEGY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_5766;    
    Conclusion This study highlights the promising efficacy of EFTR for locally advanced ESCC following conversion therapy, proposing an esophageal preservation approach for patients who are either unsuitable for or decline surgical intervention. Although the EFTR-based esophageal preservation strategy shows considerable benefits, it necessitates validation through more extensive, prospective clinical trials to establish its efficacy and safety in the advanced ESCC patients.